{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:45:06Z","timestamp":1759340706869,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Previous report showed that a variety of icotinib derivatives bearing different 1,2,3-triazole moieties, which could be readily prepared <jats:italic>via<\/jats:italic> copper (I)-catalyzed cycloaddition (CuAAC) reaction between icotinib and different azides, exhibited interesting activity against different lung cancer cell lines such as H460, H1975, H1299, A549 or PC-9. To further expand the application scope of the compounds and to validate the function of triazole groups in drug design, the anti-cancer activity of these compounds against esophageal squamous carcinoma (ESCC) cells was tested herein. Preliminary MTT experiments suggested that these compounds were active against different ESCC cell lines such as KYSE70, KYSE410, or KYSE450 as well as their drug-resistant ones. Especially, compound 3l showed interesting anticancer activity against these cell lines. The mode of action was studied <jats:italic>via<\/jats:italic> molecular docking, SPR experiments and other biochemical studies, and 3l exhibited higher binding potential to wild-type EGFR than icotinib did. <jats:italic>In vivo<\/jats:italic> anticancer study showed that 3l could inhibit tumor growth of cell-line-derived xenografts in ESCC. Study also suggested that 3l was a potent inhibitor for EGFR-TK pathway. Combining these results, 3l represents a promising lead compound for the design of anti-cancer drugs against ESCC.<\/jats:p>","DOI":"10.3389\/fphar.2022.1028692","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T06:43:42Z","timestamp":1668581022000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaojie","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long-Fei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueli","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqiong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu-Kuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zigang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/1078155220930285","article-title":"A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care","volume":"26","author":"Al-Quteimat","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1053\/j.semtcvs.2019.12.008","article-title":"Presentation, treatment, and outcomes of vulnerable populations with esophageal cancer treated at a safety-net hospital","volume":"32","author":"Asokan","year":"2020","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/onc.2009.150","article-title":"Combined genomic and gene expression microarray profiling identifies ECOP as an upregulated gene in squamous cell carcinomas independent of DNA amplification","volume":"28","author":"Baras","year":"2009","journal-title":"Oncogene"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1007\/s12035-018-1294-3","article-title":"Astragaloside VI promotes neural stem cell proliferation and enhances neurological function recovery in transient cerebral ischemic injury via activating EGFR\/MAPK signaling cascades","volume":"56","author":"Chen","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/neuonc\/nox191","article-title":"EGFR heterogeneity and implications for therapeutic intervention in glioblastoma","volume":"20","author":"Eskilsson","year":"2018","journal-title":"Neuro. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/ijc.21454","article-title":"EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus","volume":"118","author":"Hanawa","year":"2006","journal-title":"Int. J. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jtho.2016.02.020","article-title":"Icotinib in patients with pretreated advanced esophageal squamous cell carcinoma with EGFR overexpression or EGFR gene amplification: A single-arm, multicenter phase 2 study","volume":"11","author":"Huang","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1200\/jco.2014.59.0166","article-title":"Evidence-based diagnostic algorithm for glioma: Analysis of the results of Pathology panel review and molecular parameters of EORTC 26951 and 26882 trials","volume":"33","author":"Kros","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.001","article-title":"Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures","volume":"174","author":"Lee","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-018-0651-z","article-title":"Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/s0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet (London, Engl."},{"key":"B13","first-page":"346","article-title":"Detection and significance of epidermal growth factor receptor mutation in esophageal, esophagogastric junction and gastric cancers","volume":"36","author":"Lyu","year":"2014","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","first-page":"104421","DOI":"10.1016\/j.bioorg.2020.104421","article-title":"Design, synthesis and antitumor activity of icotinib derivatives","volume":"105","author":"Mao","year":"2020","journal-title":"Bioorg. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3760\/cma.j.cn112152-20191112-00729","article-title":"Epidemiological characteristic and current status of surgical treatment for esophageal cancer by analysis of national registry database","volume":"42","author":"Mao","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1200\/jco.2010.28.15_suppl.4108","article-title":"A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer","volume":"28","author":"Meluch","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/(sici)1096-987x(19981115)19:14<1639::aid-jcc10>3.0.co;2-b","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ijc.10173","article-title":"Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo","volume":"98","author":"Naruse","year":"2002","journal-title":"Int. J. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/0885328218809019","article-title":"Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD","volume":"33","author":"Ren","year":"2018","journal-title":"J. Biomater. Appl."},{"key":"B21","first-page":"831","article-title":"A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians","volume":"12","author":"Rizvi","year":"2013","journal-title":"Excli. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-020-00909-8","article-title":"New targets in lung cancer (excluding EGFR, ALK, ROS1)","volume":"22","author":"Russo","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/ijc.21512","article-title":"Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer","volume":"118","author":"Sutter","year":"2010","journal-title":"Int. J. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/wjon1254","article-title":"Esophageal cancer: An updated surveillance epidemiology and end results database analysis","volume":"11","author":"Then","year":"2020","journal-title":"World J. Oncol."},{"key":"B25","first-page":"3591","article-title":"Direct cloning of human neuroblastoma cells in soft agar culture","volume":"40","author":"Von Hoff","year":"1980","journal-title":"Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/cncr.22445","article-title":"Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: Association with poor outcome","volume":"109","author":"Wang","year":"2007","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/jcrt.JCRT_735_17","article-title":"Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment","volume":"14","author":"Xu","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1586\/17474124.2016.1140036","article-title":"Targeted therapy in esophageal cancer","volume":"10","author":"Zhang","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1028692\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T06:43:48Z","timestamp":1668581028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1028692\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":28,"alternative-id":["10.3389\/fphar.2022.1028692"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1028692","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"article-number":"1028692"}}